Global Meningococcal Vaccines Market Industry Overview and Forecast to 2031 – Market Analysis and Market Share

Global Meningococcal Vaccines Market - Industry Overview

Meningococcal diseases primarily affect the meninges, which are the protective membranes covering the brain and spinal cord. National Meningitis Association reports that approximately 600 to 1,000 people contract meningococcal disease each year in the U.S. 21% of meningococcal disease is contracted by preteens, teens and young adults.  Evidently, these stats are driving the demand for vaccines and effective cures.  In order to prevent the rising incidences of Meningococcal diseases, such as meningitis and sepsis caused by Neisseria meningitides bacteria, advancements in vaccine technology and the rise of comprehensive vaccination programs are being actively adopted.  Predominance of upgraded vaccines and extensive vaccination drive is stimulating the growth of the global meningococcal vaccines market.

Data Bridge Market Research Market Report provides details of new recent developments, market share, market trends on the basis of its segmentations and regional analysis, the impact of market players, analyses of opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market, contact Data Bridge Market Research’s team of expert analysts. Our team will help you make informed market decisions to achieve business growth.

Global Meningococcal Vaccines Market Size

Meningococcal diseases pose severe health risks, with 10-15% of affected individuals succumbing to the illness. Among survivors, approximately 20% endure permanent disabilities, such as brain damage, hearing loss, kidney failure, or limb amputations. These alarming statistics underscore the urgency for comprehensive vaccination programs and advancements in vaccine technology, which are pivotal in mitigating the impact of these life-threatening conditions. Consequently, the demand for effective meningococcal vaccines continues to drive market expansion and innovation. As a result Databridge Market Research dived into comprehensively analyzing the market and unveiled that the Global Meningococcal Vaccines   Market is increasing at a CAGR of 6.70%. Our detailed analysis forecasts that the market is valued at USD 3.49 million in 2023 and is expected to grow up to USD 5.50 million by 2031. Our meticulously created report, developed through comprehensive research and analytics, is a distinguished paper that unveils eye-opening data about the market.

Global Meningococcal Vaccines Market Dynamics

Global Meningococcal Vaccines Market Growth Drivers

Progress in Vaccine Technology

Innovations such as the development of multi-valent vaccines that cover multiple serogroups (A, B, C, W, Y) are expanding protection and driving market growth. For instance, the introduction of the MenB-FHbp vaccine targets serogroup B strains more effectively. Such advancements in vaccine technology not only expand coverage but also drive increased meningococcal vaccines market demand.

Increasing Prevalence of Meningococcal Diseases

According to Centers for Disease Control and Prevention U.S. Cases of meningococcal disease have increased sharply since 2021 and now exceed pre-pandemic levels. In 2023, 422 confirmed and probable cases were reported. This is the largest number of the U.S. meningococcal disease cases reported since 2014. This rise in disease incidence underscores the urgent need for effective vaccination programs, fueling demand for meningococcal vaccines and contributing to Global Meningococcal Vaccines Market Growth.

Global Meningococcal Vaccines Market growth Opportunities

Increasing Research and Development Initiatives

The presence of multiple existing vaccines and ongoing Phase III research activities, with several vaccines expected to be commercialized during the forecast period, is projected to drive market growth. For instance, in June 2020, Pfizer, Inc. began Phase III clinical trials for PF-06886992, a pentavalent meningococcal vaccine candidate (MenABCWY), to assess and compare its safety, immunogenicity, and tolerability with current licensed meningococcal vaccines in adolescents and young adults.

Government Initiatives and Funding

Government support and funding for meningococcal vaccination programs offer significant opportunities for market expansion. Initiatives from organizations such as GAVI and various national health agencies are facilitating vaccine accessibility and affordability. For instance, in Australia, the National Immunization Program provides free meningococcal vaccines to infants and adolescents, ensuring widespread vaccination and reducing disease incidence thereby driving market growth through enhanced public health efforts.

Global Meningococcal Vaccines Market growth Challenges

Limited Access in Low-Income Regions

In many developing countries, healthcare infrastructure and distribution networks are underdeveloped, making it difficult to reach remote or underserved populations. For instance, in regions of sub-Saharan Africa where meningococcal disease is prevalent, logistical challenges and financial constraints can hinder vaccine distribution and uptake.

Vaccine Hesitancy and Low Uptake

Despite the availability of meningococcal vaccines, some communities may harbor concerns or misconceptions about their safety and efficacy, which can hinder vaccination efforts. For instance, in parts of India, misinformation about vaccines has resulted in lower uptake rates, especially in rural areas with limited access to reliable health information. This challenge impacts the global meningococcal vaccines market by reducing vaccination coverage and effectiveness

Global Meningococcal Vaccines Market Restraints

Restraining regulatory Compliances

In Brazil, the Agência Nacional de Vigilância Sanitária (ANVISA) regulates vaccine safety and efficacy, while Australia’s Therapeutic Goods Administration (TGA) sets its own standards for vaccine approval. Adapting to these varied regulatory requirements across different markets can be complex and resource-intensive for vaccine manufacturers, potentially hindering Global Meningococcal Vaccines Market growth.

Global Meningococcal Vaccines Market Scope and Trends

• The bivalent MenACWY vaccine has been updated to enhance its efficacy and broaden coverage, addressing evolving strains against both serogroups A and C and improving protection against meningococcal disease.
• The MenB vaccines, Bexsero and Trumenba, have been incorporated into vaccination schedules for infants, offering protection against serogroup B, which is prevalent in young children.
• The FDA approved the MenQuadfi vaccine, a quadrivalent meningococcal vaccine that provides protection against serogroups A, C, W, and Y, and is now recommended for adults, including those at higher risk such as travelers and military personnel.

Global Meningococcal Vaccines Market Regional Analysis – Market Trends

Key Insights

• North American region is driven by high vaccination coverage and government initiatives. The United States leads with robust immunization programs, supported by CDC guidelines that promote routine vaccination for adolescents and at-risk populations.
• Asia-Pacific’s rapidly growing markets like India and China are witnessing increased adoption due to rising awareness and government efforts to include meningococcal vaccines in national immunization programs. However, challenges like vaccine hesitancy in rural areas persist.
•  Europe's market benefits from strong healthcare infrastructure and government-backed vaccination campaigns, particularly in the UK, where the NHS includes meningococcal vaccines in the national immunization schedule.
• Middle Eastern & African region is experiencing growth due to international health organizations’ efforts, such as GAVI, focusing on expanding vaccine coverage to prevent serotype A outbreaks in the African meningitis belt.

Global Meningococcal Vaccines Market Leading Players

• Johnson & Johnson Private Limited (U.S.)
• Mylan N.V. (U.S.)
• Sun Pharmaceutical Industries Limited (India)
• Sanofi S.A.(France)
• Merck & Co., Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• AbbVie Inc. (U.S.)
• Fresenius Kabi AG (Germany)
• Amneal Pharmaceuticals LLC. (U.S.)
• Pfizer Inc. (U.S.)
• Serum Institute of India Pvt. Ltd (India)
• Incepta Pharmaceuticals Ltd. (India)
• Walvax Biotechnology Co., Ltd (China)
• Bio-Manguinhos (Brazil)

Global Meningococcal Vaccines Market Recent Developments

• In May, 2024 FDA accepts GSK’s pentavalent meningococcal vaccine for review.
• In April, 2024 in a world first, Nigeria has introduced a new 5-in-1 vaccine targeting meningitis, aiming to enhance protection against multiple strains of the disease.
• In June, 2024 Biovac has secured agreements with Sanofi and EuBiologics to strengthen the supply of polio and meningitis vaccines across Africa, enhancing the continent's vaccine availability and healthcare infrastructure.
• In December, 2024 Pfizer's Penbraya vaccine has received USFDA approval to protect against the most common serogroups responsible for causing meningococcal disease in adolescents.

SKU-57165